Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study

@article{Kim2019UseOF,
  title={Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study},
  author={Nam Hoon Kim and Ki Hoon Han and Jimi Choi and Juneyoung Lee and Sin Gon Kim},
  journal={The BMJ},
  year={2019},
  volume={366}
}
Abstract Objective To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting. Design Propensity matched cohort study. Setting Population based cohort in Korea. Participants 29 771 adults with metabolic syndrome (≥40 years) receiving statin treatment. 2156 participants receiving combined treatment (statin plus fenofibrate) were weighted based on propensity score in a 1:5 ratio with 8549… 

Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study

TLDR
The combination of ezetimibe in addition to statin treatment was not associated with a significantly different risk of T2D and CVDs compared with statin monotherapy in Korean adults with IFG.

Remnant cholesterol is associated with cardiovascular mortality

TLDR
Elevated RC levels were associated with cardiovascular mortality independent of traditional risk factors, and this population comprised 19,650 adults in the United States from the National Health and Nutrition Examination Survey (NHANES) from 1999-2014.

Cardiovascular risks associated with calcium supplementation in patients with osteoporosis: a nationwide cohort study.

TLDR
It is supported that taking calcium supplementation with vitamin D together did not appear to be harmful to cardiovascular health, but reminding that calcium supplementation without vitamin D should be used carefully even in populations with low dietary calcium intake.

The Efficacy of Fenofibrate in Addition to Atorvastatin in Patients of Type II Diabetes Mellitus

TLDR
Overall, both groups showed significant improvements in lipid profiles; however, when atorvastatin in addition to fenofibrate was compared with saroglitazar, it was found that the latter combination was more effective in improving the overall patient outcome.

Therapy and clinical trials.

  • A. Kalhan
  • Medicine
    Current opinion in lipidology
  • 2020
TLDR
The strength of this study includes the use of fibrates in a real-life clinical setting in patients with high-risk atherogenic dyslipidaemia, although the risk of composite CVD events was significantly lower in the participants on combined therapy as compared with the ones on statin monotherapy.

Combined lipid-lowering therapy from standpoint of modern guidelines for management of dyslipidaemias

TLDR
It can be expected that the widespread use of rosuvastatin and fenofibrate in clinical practice will effectively reduce the residual cardiovascular risk and thus provide an improved prognosis for patients.

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

TLDR
A common PPARA regulatory variant is found that influences the cardiovascular effects of fen ofibrate and that could be used to identify patients with type 2 diabetes who would derive benefit from fenofibrate treatment, in addition to those with atherogenic dyslipidemia.

Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation

TLDR
The results suggest the risk of new-onset atrial fibrillation remained elevated up to 3 years in treated primary aldosteronism compared with essential hypertension, which declined to comparable risk in essential hypertension thereafter.

References

SHOWING 1-10 OF 50 REFERENCES

Effects of combination lipid therapy in type 2 diabetes mellitus.

TLDR
The routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes does not support the routine use.

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes

TLDR
In individual patients with T2DM, there is a wide range of absolute treatment effect of fen ofibrate, and overall the fenofibrate treatment effect was larger in patients with dyslipidemia.

Ezetimibe added to statin therapy after acute coronary syndromes

TLDR
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes and lowering LDL cholesterol to levels below previous targets provided additional benefit.

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

TLDR
Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

TLDR
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes, and lowering LDL cholesterol to levels below previous targets provided additional benefit.

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

TLDR
The meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality.

Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD

TLDR
A role for fenofibrate, in addition to statin therapy and lifestyle intervention, for reducing global vascular risk in type 2 diabetes patients and for impacting atherogenic dyslipidaemia associated with the metabolic syndrome is suggested.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

TLDR
In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.

Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans

TLDR
Hypertriglyceridemia is independently associated with an increased risk for CVD, especially in nonobese, normotensive, or nondiabetic individuals, when the analysis was stratified according to BMI, hypertension, and glycemic status at baseline.